JP Morgan Chase’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.49M | Sell |
10,000
-11,000
| -52% | -$8.42M | ﹤0.01% | 2950 |
|
|
2025
Q4 | $16.2M | Sell |
21,000
-400
| -2% | -$272K | ﹤0.01% | 2245 |
|
|
2025
Q3 | $12M | Sell |
21,400
-35,800
| -63% | -$20.2M | ﹤0.01% | 2560 |
|
|
2025
Q2 | $30M | Buy |
57,200
+34,100
| +148% | +$19M | ﹤0.01% | 1656 |
|
|
2025
Q1 | $14.7M | Sell |
23,100
-20,000
| -46% | -$13.8M | ﹤0.01% | 2190 |
|
|
2024
Q4 | $30.7M | Buy |
43,100
+1,000
| +2% | +$839K | ﹤0.01% | 1653 |
|
|
2024
Q3 | $44.3M | Buy |
42,100
+10,000
| +31% | +$11.1M | ﹤0.01% | 1402 |
|
|
2024
Q2 | $33.7M | Sell |
32,100
-2,900
| -8% | -$2.81M | ﹤0.01% | 1475 |
|
|
2024
Q1 | $33.7M | Sell |
35,000
-7,400
| -17% | -$7.04M | ﹤0.01% | 1526 |
|
|
2023
Q4 | $37.2M | Buy |
42,400
+9,500
| +29% | +$7.82M | ﹤0.01% | 1388 |
|
|
2023
Q3 | $27.1M | Buy |
32,900
+200
| +0.6% | +$157K | ﹤0.01% | 1462 |
|
|
2023
Q2 | $23.5M | Sell |
32,700
-137,200
| -81% | -$106M | ﹤0.01% | 1588 |
|
|
2023
Q1 | $140M | Buy |
169,900
+148,300
| +687% | +$112M | 0.02% | 668 |
|
|
2022
Q4 | $15.6M | Buy |
21,600
+21,100
| +4,220% | +$15.6M | ﹤0.01% | 1863 |
|
|
2022
Q3 | $344K | Hold |
500
| – | – | ﹤0.01% | 4672 |
|
|
2022
Q2 | $296K | Hold |
500
| – | – | ﹤0.01% | 4865 |
|
|
2022
Q1 | $349K | Buy |
+500
| New | +$316K | ﹤0.01% | 4905 |
|
|
2021
Q3 | – | Sell |
-400
| Closed | -$223K | – | 6730 |
|
|
2021
Q2 | $223K | Buy |
+400
| New | +$203K | ﹤0.01% | 5178 |
|
|
2021
Q1 | – | Sell |
-15,500
| Closed | -$7.49M | – | 6298 |
|
|
2020
Q4 | $7.49M | Hold |
15,500
| – | – | ﹤0.01% | 2449 |
|
|
2020
Q3 | $8.89M | Hold |
15,500
| – | – | ﹤0.01% | 2126 |
|
|
2020
Q2 | $9.67M | Hold |
15,500
| – | – | ﹤0.01% | 1922 |
|
|
2020
Q1 | $7.57M | Sell |
15,500
-7,100
| -31% | -$2.93M | ﹤0.01% | 1946 |
|
|
2019
Q4 | $8.49M | Sell |
22,600
-1,400
| -6% | -$471K | ﹤0.01% | 2255 |
|
|
2019
Q3 | $6.66M | Buy |
24,000
+2,500
| +12% | +$740K | ﹤0.01% | 2455 |
|
|
2019
Q2 | $6.68M | Buy |
21,500
+8,200
| +62% | +$2.73M | ﹤0.01% | 2417 |
|
|
2019
Q1 | $5.46M | Sell |
13,300
-166,700
| -93% | -$68.6M | ﹤0.01% | 2523 |
|
|
2018
Q4 | $67.2M | Buy |
180,000
+91,600
| +104% | +$33.5M | 0.02% | 780 |
|
|
2018
Q3 | $35.7M | Sell |
88,400
-4,600
| -5% | -$1.75M | 0.01% | 1230 |
|
|
2018
Q2 | $32.1M | Buy |
93,000
+3,700
| +4% | +$1.16M | 0.01% | 1248 |
|
|
2018
Q1 | $30.8M | Buy |
89,300
+23,900
| +37% | +$8.31M | 0.01% | 1235 |
|
|
2017
Q4 | $24.6M | Buy |
65,400
+10,600
| +19% | +$4.29M | 0.01% | 1426 |
|
|
2017
Q3 | $23.8M | Buy |
54,800
+45,200
| +471% | +$21.5M | 0.01% | 1383 |
|
|
2017
Q2 | $4.71M | Sell |
9,600
-7,300
| -43% | -$3.19M | ﹤0.01% | 2510 |
|
|
2017
Q1 | $6.55M | Buy |
+16,900
| New | +$6.26M | ﹤0.01% | 2243 |
|
Other funds holding REGN
VCM
N
JP Morgan Chase's REGN Position: Q1 2026 in Review
JP Morgan Chase increased its Regeneron Pharmaceuticals (REGN) stake by 9.4% in Q1 2026, buying an estimated $285M and bringing the position to 4,311,806 shares worth $3.23B. The position accounts for 0.21% of the portfolio, ranked #106.
JP Morgan Chase first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.7B in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- JP Morgan Chase held 4,311,806 shares of Regeneron Pharmaceuticals worth $3.23B as of Q1 2026.
- JP Morgan Chase bought 371,646 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $285M.
- Regeneron Pharmaceuticals made up 0.21% of JP Morgan Chase's portfolio in Q1 2026, its #106 holding.
- JP Morgan Chase first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Regeneron Pharmaceuticals position peaked at $8.7B in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.